Compare Crispr Therapeutics AG (CRSP) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Nucor Corporation — how do they compare? Crispr Therapeutics AG trades at $50.93 (market cap $4.97B), while Nucor Corporation trades at $234.51 (market cap $53.33B). The key difference: Nucor Corporation is far larger — about 10.7× Crispr Therapeutics AG's market cap, and Nucor Corporation pays a 0.96% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | NUE | |
|---|---|---|
Market Cap | $4.97B | $53.33B |
Sector | Health | Basic Materials |
52-Week High | $76.78 | $266.35 |
52-Week Low | $44.34 | $131.78 |
Enterprise Value | $3.32B | $57.97B |
Dividend Yield | — | 0.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Nucor (NUE) trades at $233.00, up 2.48% over the past day, supported by a bullish technical signal and strong earnings beats in recent quarters. The stock benefits from a solid balance sheet with a debt-to-asset ratio of 20.23% (2025 company filing) and a 53-year dividend growth streak. Revenue for 2025 was $32.49 billion, with net income of $1.74 billion, though margins have compressed from peak levels. Recent news highlights a joint venture to address power infrastructure bottlenecks and positive analyst sentiment.
Outlook remains positive with a consensus price target of $262.89 (analyst reports July 2026), implying ~13% upside. Key opportunities include steel price strength and strategic expansions, but risks involve cyclical demand weakness and margin pressure. Institutional ownership trends and buy ratings (62.5% of analysts) support a constructive view, though investors should monitor Q2 2026 earnings for confirmation of guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
